Nanoparticle Poxvirus Vaccines for Scalable Neutralizing Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against poxviruses, such as the mpox vaccine Jynneos, are difficult to manufacture in large quantities and do not completely prevent infection, and there is a waning immunity in younger generations due to the cessation of smallpox vaccination, necessitating improved vaccines with enhanced neutralizing responses.
Innovation Solution
Development of nanoparticle-derived vaccines comprising nanoparticles with attached poxvirus antigens, such as L1, A33, and B5 proteins, to elicit an immune response against poxviruses like monkeypox.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current mpox vaccine (Jynneos) is used, then some protection against monkeypox is provided, but manufacturing in large quantities is difficult and does not completely prevent infection
Solution Approach 1:
The vaccine approach segments the viral infection process by targeting specific viral proteins (L1, A33, B5) as separate antigen components. These segmented protein elements are displayed on nanoparticle platforms, allowing independent optimization of each antigen's immunogenicity while simplifying manufacturing compared to whole-virus approaches.
Solution Approach 2:
The patent uses nanoparticle platforms that replicate and display viral protein structures without requiring actual viral replication. The nanoparticle system creates artificial copies of viral antigens that mimic the native viral structure and elicit protective immunity, eliminating the need for large-scale viral cultivation while maintaining immunogenicity.
2Reliability
If routine smallpox vaccination ended in 1972, then smallpox elimination was achieved, but immunity wanes in older generations and younger generations have never received the vaccine
Solution Approach 1:
The patent modifies the vaccination approach by changing the antigen delivery parameters - using nanoparticle platforms with specific protein compositions (L1, A33, B5) that are optimized for eliciting robust neutralizing antibodies. This parameter change in antigen presentation maintains long-term immunity while being suitable for both older and younger generations.
3Reliability
If nanoparticle-derived vaccines with multiple poxvirus antigens are used, then enhanced neutralizing response is elicited, but device complexity increases
Solution Approach 1:
The patent merges multiple poxvirus antigens (L1, A33, B5 proteins) onto a single nanoparticle platform. This consolidation approach allows simultaneous presentation of multiple antigenic elements that work synergistically to enhance neutralizing response, while the modular nanoparticle structure actually simplifies manufacturing compared to assembling separate viral components.
Data Source
AI summary
The present disclosure relates generally to vaccines against orthopoxviruses, and methods for making and using such vaccines. In particular, in some embodiments, the present disclosure relates to nanoparticle-derived vaccines, and compositions based thereon, that elicit an immune response against an orthopoxvirus. The present disclosure further relates to the use of vaccines and vaccine compositions for preventing; decreasing the severity, morbidity and/or mortality of; shortening the duration of; and/or reducing the symptoms of, a poxvirus infection, such as, for example, an orthopoxvirus infection.